BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8648376)

  • 1. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Herskovic T; Hanley D; Markowitz A; Dunn R; Siegel J; Kamal T; Goldenberg DM
    J Clin Oncol; 1996 Apr; 14(4):1209-17. PubMed ID: 8648376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Hanley D; Herskovic T; Markowitz A; Siegel J; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
    Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Herskovic T; Pereira M; Rubin AD; Hanley D; Dunn R; Siegel J; Goldenberg DM
    J Nucl Med; 1996 Jun; 37(6):905-11. PubMed ID: 8683309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies.
    Juweid M; Sharkey RM; Swayne LC; Goldenberg DM
    Surgery; 1997 Dec; 122(6):1156-65. PubMed ID: 9426433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
    Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
    J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
    Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
    Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R; Juweid M; Mattes MJ; Goldenberg DM
    Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
    Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization of I-131-labeled goat and primate anti-carcinoembryonic antigen(CEA) antibodies in patients with cancer.
    Sullivan DC; Silva JS; Cox CE; Haagensen DE; Harris CC; Briner WH; Wells SA
    Invest Radiol; 1982; 17(4):350-5. PubMed ID: 6752092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.
    Rufini V; Castaldi P; Treglia G; Perotti G; Gross MD; Al-Nahhas A; Rubello D
    Biomed Pharmacother; 2008 Mar; 62(3):139-46. PubMed ID: 17892924
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery.
    Arslan N; Ilgan S; Yuksel D; Serdengecti M; Bulakbasi N; Ugur O; Ozguven MA
    Clin Nucl Med; 2001 Aug; 26(8):683-8. PubMed ID: 11452174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
    Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technetium-99m-sestamibi scanning in recurrent medullary thyroid carcinoma.
    Learoyd DL; Roach PJ; Briggs GM; Delbridge LW; Wilmshurst EG; Robinson BG
    J Nucl Med; 1997 Feb; 38(2):227-30. PubMed ID: 9025742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of different scintigraphic techniques to the management of medullary thyroid carcinoma.
    Sandrock D; Blossey HC; Steinroeder M; Munz DL
    Henry Ford Hosp Med J; 1989; 37(3-4):173-4. PubMed ID: 2576957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group.
    Moffat FL; Pinsky CM; Hammershaimb L; Petrelli NJ; Patt YZ; Whaley FS; Goldenberg DM
    J Clin Oncol; 1996 Aug; 14(8):2295-305. PubMed ID: 8708720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.